Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA: 2016-2024

Historic EBITDA for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to -$84.9 million.

  • Dianthus Therapeutics' EBITDA fell 50.07% to -$36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.9 million, marking a year-over-year decrease of 91.04%. This contributed to the annual value of -$84.9 million for FY2024, which is 95.88% down from last year.
  • As of FY2024, Dianthus Therapeutics' EBITDA stood at -$84.9 million, which was down 95.88% from -$43.3 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' EBITDA registered a high of -$28.6 million during FY2022, and its lowest value of -$84.9 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$43.3 million (2023), whereas its average is -$52.3 million.
  • Data for Dianthus Therapeutics' EBITDA shows a maximum YoY tumbled of 95.88% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' EBITDA (Yearly) stood at -$28.6 million in 2022, then slumped by 51.37% to -$43.3 million in 2023, then crashed by 95.88% to -$84.9 million in 2024.